pISSN 1226-6051
eISSN 2508-786X

Table. 4.

Table. 4.

Clinical manifestations of PD-1 inhibitors therapy associated thyroid-related adverse events (n=43)

Medication Total (n=43) P-value

Nivolumab (n=21) Pembrolizumab (n=22)
Age, mean (SD), years 64.4 (9.9) 61.0 (14.4) 62.7 (12.4) 0.370
Sex, n(%) 0.109
Male 17 (81.0) 13 (59.1) 30 (69.8)
Female 4 (19.0) 9 (40.9) 13 (30.2)
Cancer type, n(%) 0.176
NSCLC 12 (57.1) 10 (45.5) 22 (51.2)
Malignant melanoma 5 (23.8) 9 (40.9) 14 (32.6)
Lymphoma 0 (0.0) 2 (9.1) 2 (4.7)
Bladder ca 0 (0.0) 1 (4.5) 1 (2.3)
RCC 1 (4.8) 0 (0.0) 1 (2.3)
Leiomyosarcoma 1 (4.8) 0 (0.0) 1 (2.3)
Number of PD-1inhibitors cycle,median(range) 8 (3-37) 5.5 (1-21) 7 (1-37) 0.067
Clinician consultation, n(%) 0.412
Yes 4 (19.0) 3 (13.6) 7 (16.3)
No 17 (81.0) 19 (86.4) 36 (83.7)
Medical therapy, n(%) 0.664
Yes 3 (14.3) 2 (9.1) 5 (11.6)
No 18 (85.7) 20 (90.9) 38 (88.4)
Treatment, n(%) 0.057
Thyroxine 3 (14.3) 1 (4.5) 4 (9.3)
Corticosteroids 0 (0) 1 (4.5) 1 (2.3)
TFTs monitoring 13 (61.9) 7 (31.9) 20 (46.5)
None 5 (23.8) 13 (59.1) 18 (41.9)

SD, standard deviation; NSCLC, Non-small cell lung cancer; TFTs, Thyroid function tests; RCC, renal cell carcinoma

Korean J Clin Pharm 2021;31:188-97 https://doi.org/10.24304/kjcp.2021.31.3.188
© 2021 Korean J Clin Pharm